[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [@lafforug](/creator/twitter/lafforug) "Regeneron has invented&preclinically validated a proprietary antibody-directed AAV approach that builds on our decades of experience in antibodies&newly developed AAV capsid engineering tech to deliver innovative payloads across many targeted tissue types"  [@lafforug](/creator/x/lafforug) on [X](/post/tweet/1948730315351994608) 2025-07-25 13:01:27 UTC XXX followers, XXX engagements "I believe you may have forgotten that Intellia is set to complete its cost reduction efforts in Q1which the company reported today.The reduced operating costs will be reflected in Q2. Cash plus interest equals to the cash runway or $707m+$56.56m(4%interest)=$763.56m/8=$95m $NTLA"  [@lafforug](/creator/x/lafforug) on [X](/post/tweet/1920494801167745524) 2025-05-08 15:03:36 UTC XXX followers, XXX engagements "Thank you for having the courage to sell your company and idea. It has helped enormously in raising the value of CRISPR companies listed on the U.S. stock market and my $IBKR account value. 👍 $NTLA $BEAM $PRME $CRSP $MGX"  [@lafforug](/creator/x/lafforug) on [X](/post/tweet/1948745945761431670) 2025-07-25 14:03:34 UTC XXX followers, XXX engagements "Are you saying you are XXX% sure that patients who fail to respond to Dupixent will respond to $NKTR What we know for a fact is that Dupixent is approved to treat X diseases so far. And when the data is compared head-to-head for the treatment of atopic dermatitis Dupixent wins"  [@lafforug](/creator/x/lafforug) on [X](/post/tweet/1937852870310654003) 2025-06-25 12:38:22 UTC XXX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@lafforug
"Regeneron has invented&preclinically validated a proprietary antibody-directed AAV approach that builds on our decades of experience in antibodies&newly developed AAV capsid engineering tech to deliver innovative payloads across many targeted tissue types"
@lafforug on X 2025-07-25 13:01:27 UTC XXX followers, XXX engagements
"I believe you may have forgotten that Intellia is set to complete its cost reduction efforts in Q1which the company reported today.The reduced operating costs will be reflected in Q2. Cash plus interest equals to the cash runway or $707m+$56.56m(4%interest)=$763.56m/8=$95m $NTLA" @lafforug on X 2025-05-08 15:03:36 UTC XXX followers, XXX engagements
"Thank you for having the courage to sell your company and idea. It has helped enormously in raising the value of CRISPR companies listed on the U.S. stock market and my $IBKR account value. 👍 $NTLA $BEAM $PRME $CRSP $MGX" @lafforug on X 2025-07-25 14:03:34 UTC XXX followers, XXX engagements
"Are you saying you are XXX% sure that patients who fail to respond to Dupixent will respond to $NKTR What we know for a fact is that Dupixent is approved to treat X diseases so far. And when the data is compared head-to-head for the treatment of atopic dermatitis Dupixent wins" @lafforug on X 2025-06-25 12:38:22 UTC XXX followers, XXX engagements